Shanghai Aucta Pharma Co Ltd v. Zydus Pharma USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shanghai Aucta Pharmaceuticals Co. Ltd. (China); Aucta Pharmaceuticals, Inc. (Delaware)
  • Defendant: Zydus Pharmaceuticals (USA) Inc. (New Jersey); Zydus Lifesciences Ltd. (India)
  • Plaintiff's Counsel: Walsh Pizzi Oreilly Falanga LLP
• Case Identification: 1:26-cv-02954, D.N.J., 03/23/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Zydus USA Inc. is a New Jersey corporation with its principal place of business in the state, and Defendant Zydus Ltd. is a foreign corporation that may be sued in any judicial district.
• Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of Plaintiffs' MOTPOLY XR™ (lacosamide) extended-release capsules constitutes an act of infringement of three U.S. patents.
• Technical Context: The dispute centers on extended-release pharmaceutical formulations for lacosamide, an anticonvulsant drug, which are designed to enable once-daily dosing to improve patient compliance and reduce side effects associated with immediate-release versions.
• Key Procedural History: The lawsuit was triggered by a notification letter from Zydus, dated February 10, 2026, advising Plaintiffs of its ANDA filing which included a Paragraph IV Certification against the patents-in-suit. The patents are listed in the U.S. Food and Drug Administration's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book) for MOTPOLY XR™.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,337,943 - Lacosamide Pharmaceutical Composition and Dosage Form Thereof

The Invention Explained

• Problem Addressed: The patent's background section describes that immediate-release formulations of the anticonvulsant lacosamide, which require high daily doses, can cause adverse side effects such as dizziness and nausea that correlate with the maximum steady-state plasma concentration (Cmax,ss) of the drug '943 Patent, col. 1:44-54 The patent notes a clinical need for a novel dosage form of lacosamide suitable for once-daily oral administration to reduce these adverse reactions and improve patient compliance '943 Patent, col. 1:59-64
• The Patented Solution: The invention is a pharmaceutical dosage form comprising both an extended-release portion and an immediate-release portion of lacosamide, structured as a multiparticulate system '943 Patent, abstract The core concept involves a drug-loaded core particle that is coated with an extended-release layer, which itself is then enclosed by an immediate-release layer, creating a layered particulate designed to control the drug's release profile over time '943 Patent, col. 22:35-39 '943 Patent, Fig. 1
• Technical Importance: This formulation technology aims to provide the therapeutic benefits of lacosamide while mitigating the peak-concentration side effects of immediate-release versions, potentially improving safety and enabling a more convenient once-daily dosing regimen '943 Patent, col. 1:62-64

Key Claims at a Glance

• The complaint asserts infringement of at least Claim 1 of the '943 patent Compl. ¶43
• Independent Claim 1 of the '943 patent recites the following essential elements:
  • A dosage form of lacosamide comprising an extended release portion and an immediate release portion.
  • The extended release portion comprises a core containing lacosamide, which is enclosed by an extended release layer containing a pH-independent extended release agent; the core itself is free from the extended release agent.
  • The immediate release portion contains 5% to 30% of the total lacosamide and encloses the extended release portion to form a single particulate.
  • The dosage form comprises a plurality of these particulates.
  • The dosage form exhibits a specific three-part in-vitro dissolution profile over 12 hours.
  • When administered once daily, the dosage form achieves more than 90% of the Area Under the Curve (AUC) of a reference immediate-release product.

U.S. Patent No. 11,883,374 - Lacosamide Pharmaceutical Composition and Dosage Form Thereof

The Invention Explained

• Problem Addressed: The '374 patent addresses the same technical problem as the '943 patent: the need for a once-daily lacosamide formulation to reduce the adverse side effects associated with the high peak plasma concentrations of immediate-release versions '374 Patent, col. 1:41-63
• The Patented Solution: The solution is also a multiparticulate dosage form combining immediate and extended release of lacosamide '374 Patent, abstract However, this patent describes a different physical structure. The invention comprises a "first plurality" of particulates for extended release (a drug core coated with a release layer) combined with a "second plurality" of particulates that provide the immediate-release portion, suggesting a mixture of two distinct types of particles rather than a single layered particle '374 Patent, col. 13:19-24 '374 Patent, col. 21:55-61
• Technical Importance: This approach also aims to achieve a controlled, once-daily therapeutic profile for lacosamide but provides an alternative formulation architecture-a blend of different functional particles-to accomplish that goal '374 Patent, col. 1:60-63

Key Claims at a Glance

• The complaint asserts infringement of at least Claim 1 of the '374 patent Compl. ¶54
• Independent Claim 1 of the '374 patent recites the following essential elements:
  • A dosage form of lacosamide comprising a "first plurality" of particulates and an immediate release portion.
  • The first plurality of particulates (the extended release portion) each comprise a core containing lacosamide enclosed by an extended release layer with a pH-independent agent; the core is free from the extended release agent.
  • The immediate release portion is in the form of a "second plurality of particulates" and contains 5% to 30% of the total lacosamide.
  • The dosage form is configured to have a specific three-part in-vitro dissolution profile over 12 hours.

U.S. Patent No. 12,042,474 - Lacosamide Pharmaceutical Composition and Dosage Form Thereof

Technology Synopsis

• The '474 patent is directed to extended-release dosage forms of lacosamide for once-daily oral administration, intended to reduce adverse reactions seen with immediate-release versions '474 Patent, abstract '474 Patent, col. 1:63-65 The claims of this patent are defined by the in-vivo pharmacokinetic (PK) profile the dosage form achieves, specifying Area Under the Curve (AUC) values at different time intervals (e.g., AUC0-3h, AUC0-6h) relative to a reference immediate-release product '474 Patent, col. 28:13-35

Asserted Claims

• The complaint asserts infringement of at least Claim 1 Compl. ¶65

Accused Features

• The complaint alleges that Zydus's Proposed ANDA Product is a lacosamide extended-release capsule that, when administered, will meet the pharmacokinetic profile limitations recited in Claim 1 Compl. ¶66

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Zydus's Proposed ANDA Product," which is a generic version of MOTPOLY XR™ (lacosamide) extended-release capsules in 100 mg, 150 mg, and 200 mg dosage strengths Compl. ¶13 Compl. ¶32

Functionality and Market Context

The complaint alleges that Zydus's product is an extended-release dosage form containing lacosamide, submitted to the FDA for approval as a generic equivalent to Plaintiffs' branded product Compl. ¶33 Compl. ¶41 As an ANDA product, it is intended to be a lower-cost, bioequivalent alternative to the brand name drug for which the patents-in-suit are listed in the FDA's Orange Book Compl. ¶29 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

U.S. Patent No. 11,337,943 Infringement Allegations

• Identified Points of Contention:
  • Structural Questions: A primary point of contention may be the structural limitation "wherein the immediate release portion encloses the extended release portion to form a particulate." The infringement analysis will depend on whether Zydus's product utilizes this specific integrated, layered particulate architecture, or if it achieves a similar release profile through a different physical arrangement, such as a simple mixture of separate immediate-release and extended-release particles.

U.S. Patent No. 11,883,374 Infringement Allegations

• Identified Points of Contention:
  • Structural Questions: The central issue for the '374 patent is whether the accused product is formulated as a mixture of two distinct populations of particles ("a first plurality" and "a second plurality"). This raises a direct factual question about the physical composition of Zydus's product, and it notably contrasts with the "enclosing" structure claimed in the '943 patent.

V. Key Claim Terms for Construction

• The Term: "wherein the immediate release portion encloses the extended release portion to form a particulate" (from '943 Patent, Claim 1)
• Context and Importance: This term defines the core physical structure of the claimed invention in the '943 patent. The infringement analysis will likely hinge on whether Zydus's product is constructed as a single, multi-layered particle or as a mixture of different particles. Practitioners may focus on this term because it presents a specific, potentially narrow structural requirement that may not be present in all extended-release formulations.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent does not appear to provide explicit definitions that would broaden "encloses" beyond its plain meaning. A party might argue that functional enclosure, rather than a perfect physical coating, is sufficient if it results in "a particulate."
  • Evidence for a Narrower Interpretation: The phrase "to form a particulate" suggests that the enclosure results in a single, unitary particle '943 Patent, claim 1 The specification's discussion of coating layers, such as an "immediate release layer... coated outside the extended release layer," may support a narrower interpretation requiring a distinct, layered physical structure '943 Patent, col. 13:9-16
• The Term: "a first plurality of the particulates" and "a second plurality of particulates" (from '374 Patent, Claim 1)
• Context and Importance: These terms define the formulation of the '374 patent as a blend of two different types of particles-one for extended release and one for immediate release. This construction is critical because it distinguishes the invention from an integrated, single-particulate system. The question of infringement will depend on whether Zydus's product is a physical mixture of separate particle populations.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The complaint does not provide sufficient detail for analysis of evidence supporting a broader interpretation.
  • Evidence for a Narrower Interpretation: The patent specification describes that "The extended release multiparticulates and the immediate release multiparticulates can be mixed into the same capsules," which directly supports an interpretation that the two "pluralities" are physically separate and distinct populations of particles combined in the final dosage form '374 Patent, col. 13:21-24

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Defendants will indirectly infringe under 35 U.S.C. § 271(b) and/or § 271(c) Compl. ¶42 Compl. ¶53 Compl. ¶64 In the context of an ANDA case, such allegations are typically based on the proposed product labeling, which would allegedly instruct or encourage physicians and patients to administer the generic drug in a manner that practices the patented claims.
• Willful Infringement: The complaint alleges that Defendants had pre-suit knowledge of the patents-in-suit via their listing in the FDA's Orange Book and via the Zydus Notice Letter, which explicitly referenced the patents Compl. ¶45 Compl. ¶56 Compl. ¶67 The complaint further asserts that this constitutes an "exceptional" case, a predicate for seeking enhanced damages and attorneys' fees Compl. ¶48 Compl. ¶59 Compl. ¶70

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of structural infringement: what is the precise physical architecture of Zydus's proposed generic product? Does it embody the integrated, layered "enclosed" particulate structure required by the '943 patent, the blended "two pluralities of particulates" structure of the '374 patent, or a different, non-infringing design? The assertion of two distinct and potentially mutually exclusive formulation structures against the same product raises significant questions about the factual basis of the infringement allegations.
• A second key issue will be one of pharmacokinetic performance: for the '474 patent, the dispute will likely focus on clinical and bioequivalence data. Does the Zydus product, upon administration, exhibit the specific in-vivo AUC profile recited in the claims, or does its performance fall outside the claimed pharmacokinetic parameters?
• The case will also depend on claim construction: the court's interpretation of terms like "encloses" ('943 patent) versus "a second plurality of particulates" ('374 patent) will be critical. The definitions of these terms will determine the scope of the claims and could be dispositive of the infringement analysis for the formulation patents.